Journal Logo


Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases

Eyden, Briana; Ru, Yong-Xinb; Dong, Shu-Xub; Liu, Jingb; Liu, Xiao-Fanb

Author Information
doi: 10.1097/BS9.0000000000000093



In the article titled “Ultrastructural alterations of megakaryocytes in thrombocytopenia: A review of 43 cases,” published on pages 107–112, Volume 3, Issue 4 of Blood Science, a coauthor's name was incorrectly published as well as an affiliation was missing. The Journal and the authors wish to apologize for this error.

Blood Science. 4(1):47, January 2022.


Thrombocytopenia – marked primarily by low platelet counts – is regarded as a comparatively rare condition, affecting some 200,000 patients a year worldwide (data from the National Organization for Rare Diseases) and yet the patients who have this condition suffer unpleasant symptoms such as hemorrhage, rash, headache, hematuria, heavy menstruation in the case of women, malaise and fatigue, and may need medication such as auto-immune suppressants. The megakaryocyte – the cell of origin for platelets as mature elements in the blood – is clearly the focus of attention in the investigation of the mechanism of thrombocytopenia, and understanding its normal and abnormal development would be key to helping to understand thrombocytopenia.

The normal megakaryocyte undergoes a development in which 4 stages are observed morphologically. Stage I cells are characterized by blast-cell features—small size and a lack of marker structures; stage II cells have small or modest numbers of dense-core granules and α-granules, as well as early development of the demarcation membrane system (DMS) and the open canalicular system (OCS), structures which are increasingly well developed in stages III and IV; in stage IV, the granules, DMS, OCS, and pro-platelets are fully developed.1,2 By contrast, megakaryocytes in pathologic conditions – for example, idiopathic thrombocytopenic purpura (ITP), aplastic anemia, and myelodysplastic syndrome (MDS) – show abnormal structures.3

In the present study, we have studied megakaryocytes observed as incidental findings in the bone marrows of 43 patients with various blood diseases complicated by thrombocytopenia, including 5 cases of ITP, 18 of aplastic anemia, 6 of MDS, 7 of acute megakaryocytic leukemia (AMKL), and 7 of acute leukemia not of AMKL type (Table 1). All patients had low platelet counts and were diagnosed at the Institute of Hematology and Blood Diseases Hospital, Tianjin using standard procedures. The bone marrow aspirates were processed for transmission electron microscopy as previously described.4

Table 1 - Alterations of megakaryocytes in thrombocytopenia-related diseases
Cases 5 18 6 7 7
Aberrant features 4 6 5 2 2
Autophagy 0 6 0 0 0
Apoptosis 0 2 0 0 0
Cellular damage 1 4 0 0 5
Poor differentiation 1 7
AA = aplastic anemia, AMKL = acute megakaryocytic leukemia, ITP = idiopathic thrombocytopenic purpura, MDS = myelodysplastic syndrome, non-AMKL = other than AMKL.


We summarize the abnormal features of megakaryocytes to provide data which, in combination with other techniques, might in due course, point to possible mechanisms of thrombocytopenia.

2.1 Idiopathic thrombocytopenic purpura

ITP, also known as immune thrombocytopenia, is always complicated by a low platelet count and serious bleeding episodes in children.5 ITP is marked by increased platelet destruction in the circulation and decreased platelet production in the bone marrow.6 Quite apart from the destruction of platelets by autoantibodies, abnormalities of megakaryocytes, which could influence platelet production, have been noted recently.7,8 In our material, megakaryocytes exhibited an abnormally high accumulation of glycogen and increased numbers of mitochondria and DMS in 4 out of 5 cases. One case showed abundant glycogen particles around the nuclei of megakaryocytes; abnormally abundant glycogen was present in platelets too (Fig. 1). These changes are consistent with observations in morphologic reviews of ITP as well as in human subjects treated with prednisone. It was thought that glycogen accumulation in megakaryocytes and platelets resulted from the stress of autoimmune platelet destruction in ITP.9,10 One megakaryocyte was full of mitochondria but had few megakaryocytic-specific organelles—namely, granules, DSM, and OCS (Fig. 2A, B). Another megakaryocyte included massive DMS that failed to segregate cytoplasm into individual pro-platelets (Fig. 2). In addition, 1 of 5 cases showed a badly damaged megakaryocyte which featured a condensed nucleus and necrotic cytoplasm (Fig. 2).

Figure 1:
Megakaryocytes in idiopathic thrombocytopenic purpura. (A) Uneven distribution of DMS and non-segregation of the cytoplasm in a megakaryocyte, ×3k. (B) Masses of glycogen particles (arrows) around nuclear profiles in a megakaryocyte, ×3k. (C) High magnification view of glycogen (asterisk) in (B), ×12k. (D) Abundant glycogen particles in platelet of the same case (B), ×12k. DMS = demarcation membrane system.
Figure 2:
Megakaryocytes in idiopathic thrombocytopenic purpura. (A) Plentiful mitochondria, but less demarcation membrane and pro-platelets in a megakaryocyte, ×3k. (B) High magnification view of the abundant mitochondria in the cytoplasm in (A) ×10k. (C) More demarcation membrane than pro-platelets in a megakaryocyte, ×3k. (D) A necrotic megakaryocyte with a condensed nucleus and focally necrotic cytoplasm, ×3k.

Although the causative factors behind the development of these abnormalities remain to be identified, the final result is the abnormal accumulation of glycogen and mitochondria, and the abnormal distribution of DMS and OCS which interfere with platelet-production in megakaryocytes in ITP.

2.2 Aplastic anemia

Low platelet counts are a significant sign associated with the prognosis of aplastic anemia.11 Some clinical reports have indicated that alterations in megakaryocytes are associated with decreased platelets and progression in aplastic anemia.12–15 It is usually thought that thrombocytopenia results from the loss of megakaryocytes in bone marrow, although this has not been demonstrated morphologically in aplastic anemia.16

In the present study, all megakaryocytes showed pathologic changes indicating aberrant developmental features. In addition to other cytologic damage, autophagosomes, and apoptotic bodies were seen in 18 cases. Autophagy and aberrant development were predominant in 12 cases; here, megakaryocytes exhibited inclusions such as autophagosomes, autolysosomes, and lipofuscin bodies. Some of the autophagic cells were accompanied by accumulations of glycogen, lipid droplets, and vacuoles (Fig. 3).

Figure 3:
Alterations of megakaryocytes in aplastic anemia. (A) A megakaryocyte includes a large lipid droplet (asterisk), many autophagosomes, and autolysosomes, ×3k. (B) High magnification of an autophagosome (center) and autophagic vacuoles (arrows) in (A), ×12k. (C) A megakaryocyte contains numerous clumps of glycogen and autophagosomes, ×3k. (D) High magnification view of glycogen clumps and autophagosomes in (C), ×20k.

Apoptotic megakaryocytes were characterized by condensed nuclei, peripheral vesicles, and abnormal pro-platelets, the latter forming mainly in the peripheral cytoplasm. Apoptosis is a normal end-stage physiological feature in the process by which megakaryocytes shed platelets into the circulation,17 but most apoptotic megakaryocytes in aplastic anemia contained prominent rough endoplasmic reticulum (rER), lysosomes, and amorphous materials instead of pro-platelets (Fig. 4A, B). This suggests that in aplastic anemia these apoptotic megakaryocytes were experiencing pathologic change closely related to a decrease in platelets. Additionally, in 1 case of aplastic anemia, a megakaryocyte containing 3 necrotic neutrophils was observed, showing small and disruptive pro-platelets in the cytoplasm (Fig. 4C, D). We cannot explain this emperipolesis of necrotic neutrophils in megakaryocytes, and more cases need to be examined before formulating an explanation.

Figure 4:
Alterations of megakaryocytes in aplastic anemia. (A) An apoptotic megakaryocyte with a condensed nucleus, amorphous fringes (pairs of arrowheads), arrayed rER, and vesicles in the cytoplasm, ×3k. (B) An apoptotic megakaryocyte, ×3k. (C) Three necrotic neutrophils in a damaged megakaryocyte; arrowheads indicate interface between neutrophil and the megakaryocyte, ×4k. (D) High magnification view of the boundary membrane (arrowheads) in (C), ×8k.

In summary, it is reasonable to assume that excessive autophagy, apoptosis, and cellular damage in megakaryocytes have some, as yet undefined, role in low platelet production, but nevertheless constitute an ultrastructural characteristic of thrombocytopenia in aplastic anemia.

2.3 Myelodysplastic syndrome

While formerly considered a form of pre-leukemia, MDS is regarded as a malignant myeloid hematopoietic condition often characterized by certain genetic mutations and morphologic alterations. Most patients have the complications of low platelet count in the circulation and abnormalities of megakaryocytes in the bone marrow18,19 and these 2 features are associated with the progression and prognosis of the disease.20,21 Some recent case reports have reported morphologic alterations of megakaryocytes in bone marrow from MDS patients.22,23

In the present study, megakaryocytes from MDS patients were characterized by an asymmetric development of nucleus and cytoplasm, and aberrant distribution of cytoplasmic organelles in 5 out of 6 cases; in the 1 remaining case, megakaryocytes showed poorly differentiated features.

Most of the asymmetrically developed megakaryocytes had a small diameter of 10 to 15 μm, but showed mature characteristics including a small nucleus, α-granules, dense core-granules, DMS, and OCS, but fewer pro-platelets in the cytoplasm. Some of them enclosed activated lymphocytes in a process resembling emperipolesis (Fig. 5). The small size of the megakaryocytes was usually thought to result from a failure of chromosomal polyploidization and synchronous cytoplasmic expansion.24,25

Figure 5:
Asymmetric development of megakaryocytes in myelodysplastic syndrome. (A) A small megakaryocyte with a diameter of 12 μm contains plentiful pro-platelets in the cytoplasm, ×5k. (B) High magnification view of fully developed dense core-granules in the megakaryocyte in (A), ×15k. (C) A small megakaryocyte with a large nucleus in less cytoplasm includes an activated lymphocyte (Lc), ×3k. (D) A small megakaryocyte with an amorphous marginal zone contains a huge nucleus and lymphocyte (Lc), ×3k.

Another alteration of megakaryocytes is the uneven distribution of DMS and OCS in the cytoplasm as a result of which pro-platelets were not demarcated properly. Some DMS and OCS were stacked focally and presented with structural abnormalities, instead of segregating cytoplasm into pro-platelets as in normal megakaryocytes (Fig. 6A, B). It may be a causative factor in the megakaryocyte failure to produce platelets in the bone marrow in MDS patients. Additionally, megakaryocytes exhibited undifferentiated and damaged features in 1 of 6 cases (Fig. 6C, D).

Figure 6:
Aberrant megakaryocytes in myelodysplastic syndrome. (A) Abnormal DMS on 1 side but dense granules on the other side of a megakaryocyte, ×5k. (B) Abnormal DMS accumulated in the center of a megakaryocyte, ×3k. (C) An immature megakaryocyte with podocytic processes and stacked glycogen (asterisk) in the center, ×5k. (D) A megakaryocyte including numerous vesicles and fewer pro-platelets, ×5k.

Therefore, megakaryocytes in MDS presented with diverse characteristics; the significance of these features in relation to thrombocytopenia needs the further study of a larger number of cases.

2.4 Acute megakaryocytic leukemia

AMKL often occurs in children and young patients and is characterized by a proliferation of malignant progenitors of megakaryocytic lineage in the bone marrow. Most cases are complicated by low platelet count, chromosomal alterations, and abnormalities of transcriptional regulators.26

In the present study, all cases of AMKL contained stage I and stage II megakaryoblasts although in varying numbers. They were 10 to 30 μm in diameter and in 7 cases were characterized by a prominent nucleolus, a high nucleo-cytoplasmic ratio, and few specific organelles (Fig. 7). The 2 of 7 cases contained immature megakaryocytes at different stages, some of them containing DMS, OCS, and α-granules in the cytoplasm. Interestingly, the small megakaryocytes and aberrant megakaryocytes with stacked DMS which were occasionally found in AMKL were similar to those in MDS (Fig. 8). This result is consistent with other morphologic observations,27 suggesting that megakaryocytes of AMKL were poorly differentiated and shared some characteristics with those of MDS patients.

Figure 7:
Megakaryoblasts in megakaryocytic leukemia. (A) An undifferentiated megakaryoblast with a small cytoplasmic volume containing less DMS and fewer granules in the cytoplasm, ×5k. (B) A poorly differentiated megakaryoblast is characterized by expanded Golgi bodies and primary DMS, but fewer granules in the cytoplasm, ×5k. (C) A megakaryoblast includes a huge nucleus and a few lipid droplets but few organelles, ×15k. (D) Two differentiated megakaryoblasts showing prominent nuclear segmentation and primary DMS (arrowheads); N, neutrophils, ×3k.
Figure 8:
Megakaryocytes in megakaryocytic leukemia. (A) A well-developed megakaryoblast 12 μm in diameter containing a small nucleus, undeveloped DMS, and few pro-platelets in the cytoplasm, ×5k. (B) The reactivity of platelet peroxidase in a well-differentiated megakaryoblast, ×5k. (C) A well-developed megakaryoblast including aberrant DMS on 1 side of the cell but few isolated pro-platelets, ×3k. (D) Higher magnification view showing aberrant DMS and dense core granules (arrows) in (C), ×20k.

2.5 Acute leukemia of non-AMKL type

Low platelet counts are also seen in most acute leukemias of non-AMKL type, acute myeloid leukemia, and lymphoid leukemia,28 which are often complicated by the clinical feature of acquired amegakaryocytic thrombocytopenia.29,30 It is usually thought the low platelet count results from the disruption of megakaryocytic differentiation and defective thrombopoiesis in the leukemic microenvironment.31

In our study, in 7 cases, most megakaryocytes exhibited a damaged cell structure, such as vacuolization, autophagosomes, secondary lysosomes, and necrosis (Fig. 9).

Figure 9:
Megakaryocytic damage in acute leukemia of non-AMKL type. (A) A megakaryocyte surrounded by promyelocytes and containing many vesicles instead of pro-platelets in the cytoplasm in a case of AML-M2, ×3k. (B) Damaged megakaryocyte includes expanded vesicles and a monoblast (arrow) in the case of AML-M5, ×3k. (C) A necrotic megakaryocyte including many autophagosomes, secondary lysosomes, and a lytic nucleus in a case of ALL, ×3k. (D) A megakaryocyte showing the uneven distribution of DMS and lytic cytoplasm in a case of ALL, ×3k.

These images demonstrate that damaged megakaryocytes are incapacitated with regard to platelet production in bone marrow in acute leukemia of non-AMKL type, although the mechanism and especially the early steps of the process remain to be elucidated.


The alterations seen in megakaryocytes in thrombocytopenia are distinctive for different hematopoietic diseases. Aberrant megakaryocytes predominated in ITP, in aplastic anemia, and in MDS; autophagy, apoptosis, and necrosis of megakaryocytes were dominant features in aplastic anemia, while low platelet counts were associated with poorly differentiated megakaryocytes in AMKL, but with damaged megakaryocytes in acute leukemia of non-AMKL type.

Some of the ultrastructural abnormalities described here probably represent the late stages of cellular pathology in these megakaryocytes; as always in the investigation of human disease, the very earliest stages are the most difficult to investigate because they are associated with patients without overt clinical symptoms and such patients tend not to be investigated and sampled for investigation. In themselves, therefore, these ultrastructural findings cannot yet be used to construct an understanding of the underlying pathologic mechanisms which lead to these changes and which would help us to understand platelet disorders.

If we are able to develop tests to identify patients at risk of thrombocytopenia or in the very early stages of thrombocytopenia, these ultrastructural findings could form the basis of information which might in due course be integrated into the results of other investigational modalities; this offers the promise of a deeper understanding of the thrombocytopenias and hence appropriate therapy.

One line of investigation for understanding the fundamental mechanism of thrombocytopenia would be to understand the molecular and cytologic mechanism by which the DMS and the OCS drive the formation of pro-platelets and mature platelets. This is a process in which membrane is synthesized and membrane fusion occurs to produce the channels which will lead to platelet formation. SNARE proteins (soluble N-ethylmaleimide-sensitive factor attachment protein receptor) are becoming recognized as important in membrane fusion32 and these proteins have been demonstrated in a megakaryocyte cell line. Such work, where electron microscopy can be expected to play a part,33,34 offers possibilities for the detailed analysis in pathologic situations of the membrane fusion required for pro-platelet formation.


[1]. Ru YX, Dong SX, Liang HY, Zhao SX. Platelet production of megakaryocyte: a review with original observations on human in vivo cells and bone marrow. Ultrastruct Pathol 2016;40 (4):163–170. doi: 10.3109/01913123.2016.1170744.
[2]. Machlus KR, Italiano JE Jr. The incredible journey: from megakaryocyte development to platelet formation. J Cell Biol 2013;201 (6):785–796. doi: 10.1083/jcb.201304054.
[3]. Hu T, Shi XD, Feng YL, et al. Comparative study on bone marrow megakaryocytes in children with thrombocytopenic purpura, aplastic anemia and myelodysplastic syndrome. Zhonghua Er Ke Za Zhi 2005;43 (3):183–187. Chinese. PMID: 15833188.
[4]. Ru YX, Zhao SX, Dong SX, Liang HY, Wang Y. Systematic alteration of apoptosis: a review with ultrastructural observations on leukemia cells in vivo. Ultrastruct Pathol 2018;42 (1):1–9. doi: 10.1080/01913123.2017.1373176.
[5]. Yong M, Schoonen WM, Li L, et al. Epidemiology of paediatric immune thrombocytopenia in the General Practice Research Database. Br J Haematol 2010;149 (6):855–864. doi: 10.1111/j.1365-2141.2010.08176.x.
[6]. Grodzielski M, Goette NP, Glembotsky AC, et al. Multiple concomitant mechanisms contribute to low platelet count in patients with immune thrombocytopenia. Sci Rep 2019;9 (1):2208. doi: 10.1038/s41598-018-38086-1.
[7]. Mahabir VK, Ross C, Popovic S, et al. A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia. Eur J Haematol 2013;90 (2):121–126. doi: 10.1111/ejh.12041.
[8]. Hu T, Shi XD, Feng YL, et al. Study on bone marrow megakaryocytes in children patients with idiopathic thrombocytopenic purpura. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2004;12 (4):480–483.
[9]. Zucker-Franklin D, Stahl C, Hyde P. Megakaryocyte ultrastructure. its relationship to normal and pathologic thrombocytopoiesis. Ann N Y Acad Sci 1987;509:25–33. doi: 10.1111/j.1749-6632.1987.tb30979.x.
[10]. Houwerzijl EJ, Blom NR, van der Want JJ, et al. Ultrastructural study shows morphologic features of apoptosis and para-apoptosis in megakaryocytes from patients with idiopathic thrombocytopenic purpura. Blood 2004;103 (2):500–506. doi: 10.1182/blood-2003-01-0275.
[11]. Singh A, Verma A, Nityanand S, Chaudhary R, Elhence P. Circulating thrombopoietin levels in normal healthy blood donors and in aplastic anemia patients in relation to disease severity. Asian J Transfus Sci 2015;9 (1):70–73. doi: 10.4103/0973-6247.150956.
[12]. King JA, Elkhalifa MY, Latour LF. Rapid progression of acquired amegakaryocytic thrombocytopenia to aplastic anemia. South Med J 1997;90 (1):91–94. doi: 10.1097/00007611-199701000-00024.
[13]. Levy I, Laor R, Jiries N, Bejar J, Polliack A, Tadmor T. Amegakaryocytic thrombocytopenia and subsequent aplastic anemia associated with apparent Epstein–Barr virus infection. Acta Haematol 2018;139 (1):7–11. doi: 10.1159/000484595.
[14]. Ballmaier M, Germeshausen M, Krukemeier S, Welte K. Thrombopoietin is essential for the maintenance of normal hematopoiesis in humans: development of aplastic anemia in patients with congenital amegakaryocytic thrombocytopenia. Ann N Y Acad Sci 2003;996:17–25. doi: 10.1111/j.1749-6632.2003.tb03228.x.
[15]. Novotný JP, Köhler B, Max R, Egerer G. Acquired amegakaryocytic thrombocytopenic purpura progressing into aplastic anemia. Prague Med Rep 2017;118 (4):147–155. doi: 10.14712/23362936.2017.16.
[16]. McCabe A, Smith JNP, Costello A, Maloney J, Katikaneni D, MacNamara KC. Hematopoietic stem cell loss and hematopoietic failure in severe aplastic anemia is driven by macrophages and aberrant podoplanin expression. Haematologica 2018;103 (9):1451–1461. doi: 10.3324/haematol.2018.189449.
[17]. Josefsson EC, James C, Henley KJ, et al. Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 2011;208 (10):2017–2031. doi: 10.1084/jem.20110750.
[18]. Giagounidis A. Myelodysplastische syndrome. Internist (Berl) 2020;61 (2):175–184. German. doi: 10.1007/s00108-019-00718-7.
[19]. Della Porta MG, Travaglino E, Boveri E, et al. Minimal morphological criteria for defining bone marrow dysplasia: a basis for clinical implementation of WHO classification of myelodysplastic syndromes. Leukemia 2015;29 (1):66–75. doi: 10.1038/leu.2014.161.
[20]. Bussel JB. The new thrombopoietic agenda: impact on leukemias and MDS. Best Pract Res Clin Haematol 2014;27 (3–4):288–292. doi: 10.1016/j.beha.2014.10.012.
[21]. Elzaeem DI, Sharkawi EAE, Zaki EM, Ghobrial AG, El-Fatah ASA, El-Hamed WMA. Comparative study of IgG binding to megakaryocytes in immune and myelodysplastic thrombocytopenic patients. Ann Hematol 2021;100 (7):1701–1709. doi: 10.1007/s00277-021-04556-2.
[22]. Honda T, Matsukuma M, Takahashi T. Naked megakaryocyte nuclei in a patient with myelodysplastic syndrome. Intern Med 2015;54 (17):2275. doi: 10.2169/internalmedicine.54.4686.
[23]. Erkurt MA, Kaya E, Baran M, et al. Rapid progression of acquired amegakaryocytic thrombocytopenia to myelodysplastic syndrome: case report. Turk J Haematol 2005;22 (4):205–208. English. PMID: 27265013.
[24]. Mazzi S, Lordier L, Debili N, Raslova H, Vainchenker W. Megakaryocyte and polyploidization. Exp Hematol 2018;57:1–13. doi: 10.1016/j.exphem.2017.10.001.
[25]. Vainchenker W, Raslova H. Megakaryocyte polyploidization: role in platelet production. Platelets 2020;31 (6):707–716. doi: 10.1080/09537104.2019.1667497.
[26]. Lopez CK, Malinge S, Gaudry M, Bernard OA, Mercher T. Pediatric acute megakaryoblastic leukemia: multitasking fusion proteins and oncogenic cooperations. Trends Cancer 2017;3 (9):631–642. doi: 10.1016/j.trecan.2017.07.003.
[27]. Ru YX, Zhao SY, Liu JH, et al. Ultrastructural characteristics of megakaryocytes in 11 patients with acute megakaryocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2007;15 (4):720–723. Chinese. PMID: 17708790.
[28]. Qian X, Wen-jun L. Platelet changes in acute leukemia. Cell Biochem Biophys 2013;67 (3):1473–1479. doi: 10.1007/s12013-013-9648-y.
[29]. Guarini A, Sanavio F, Novarino A, Gillio Tos A, Aglietta M, Foa R. Thrombocytopenia in acute leukaemia patients treated with IL2: cytolytic effect of LAK cells on megakaryocytic progenitors. Br J Haematol 1991;79 (3):451–456. doi: 10.1111/j.1365-2141.1991.tb08054.x.
[30]. Eddou H, Zinebi A, Khalloufi A, et al. Acquired amegacaryocytic thrombocytopenic purpura hiding acute myeloid leukemia. Pan Afr Med J 2017;26:32. French. doi: 10.11604/pamj.2017.26.32.9215.
[31]. Gao A, Gong Y, Zhu C, et al. Bone marrow endothelial cell-derived interleukin-4 contributes to thrombocytopenia in acute myeloid leukemia. Haematologica 2019;104 (10):1950–1961. doi: 10.3324/haematol.2018.214593. 1.
[32]. Leabu M. Membrane fusion in cells: molecular machinery and mechanisms. J Cell Mol Med 2006;10 (2):423–427. doi: 10.1111/j.1582-4934.2006.tb00409.x.
[33]. Eckly A, Heijnen H, Pertuy F, et al. Biogenesis of the demarcation membrane system (DMS) in megakaryocytes. Blood 2014;123 (6):921–930. doi: 10.1182/blood-2013-03-492330.
[34]. Tomaiuolo M, Litvinov RI, Weisel JW, Stalker TJ. Use of electron microscopy to study platelets and thrombi. Platelets 2020;31 (5):580–588. doi: 10.1080/09537104.2020.1763939.

Blood disease; Megakaryocyte; Platelet; Thrombocytopenia; Ultrastructure

Copyright © 2021 The Authors. Published by Wolters Kluwer Health Inc., on behalf of the Chinese Association for Blood Sciences.